June 14, 2026 08:30 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Tragedy in the skies: Five IAF personnel killed in AN-32 crash in Assam | 'Ask probe officers whether I hid anything': Abhishek Banerjee hits back after pre-dawn police search | Police storm Abhishek Banerjee's house at 3 am tracking aide, Mamata arrives; seizure list says 'NIL' | Big boost for India's security: DRDO successfully tests advanced missile shield | Indian-origin man jailed for 34 years in UK over horrific kidnap, torture and rape case | Mamata's nightmare deepens! Saayoni Ghosh, Dev, Rachana Banerjee among 19 rebel MPs seeking TMC split | Trump claims US 'ended war with Iran', Tehran yet to confirm a deal | Heartbreak for Indian sports: Manu Bhaker's mentor Jaspal Rana passes away at 49 | Three Indian seafarers, missing after US strike on tanker near Oman, confirmed dead | 'Choose your side': TMC MP Kalyan Banerjee's ultimatum to Mamata in open revolt against Abhishek
Bharat Biotech-Covaxin
Image tweeted by @IndianEmbassyTR

Covaxin supplied to 18 states directly since May 1: Bharat Biotech

| @indiablooms | May 12, 2021, at 05:24 am

New Delhi/IBNS: Vaccine maker Bharat Biotech on Tuesday informed that it has directly supplied Covaxin to 18 states since May 1.

The pharmaceutical brand also urged people to get vaccinated assuring that it will continue a steady supply of vaccines to the states.

"COVAXIN® has been directly supplied to 18 states since May 1st. Unflinching in our efforts, we will continue the steady supply of our #vaccine. Get yourself and your loved ones vaccinated," the company said in a statement.

The company is supplying its vaccine directly to Andhra Pradesh, Assam, Bihar, Chhattisgarh, Delhi, Gujarat, Haryana, Jammu and Kashmir, Jharkhand, Karnataka, Madhya Pradesh, Maharashtra, Odisha, Tamil Nadu, Tripura, Telangana, Uttar Pradesh, and West Bengal.

Bharat Biotech's indigenous vaccine-Covaxin-has been developed in collaboration with the Indian Council for Medical Research (ICMR).

It was approved for emergency use by the  Drugs Controller General of India (DCGI) in January.

Covaxin has been declared to be an 81 per cent success during the Phase 3 clinical trials in India. 

On April 29, Bharat Biotech reduced the price of Covaxin from Rs 600 per dose to Rs 400 for the state governments in view of the challenges faced by the already overstretched health system, the company had said.

The vaccination programme in India which started on Jan 16, was last month widely expanded to include citizens above 18 years of age as a part of the Centre's Liberalised Pricing & Accelerated National COVID-19 Vaccination strategy.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.